癌症疫苗与免疫治疗的未来
预防性癌症疫苗通过抵御致癌病原体预防多种恶性肿瘤,而治疗性疫苗训练免疫系统消除已形成的肿瘤,现已在临床中显现真实前景。本文分析癌症疫苗试验、不同疫苗方法的优势与局限,并讨论下一代癌症疫苗如何改善患者结局与生活质量。
要点
- 预防性癌症疫苗通过抵御致癌病原体预防多种恶性肿瘤。
- 治疗性疫苗在辅助治疗中减少黑色素瘤和胰腺癌的微小残留病与复发。
- 原位疫苗在大转移灶环境中诱导晚期肺癌、乳腺癌和淋巴瘤的系统性消退。
核心结论
- 治疗性癌症疫苗在辅助治疗和大转移灶环境中显现出临床前景,下一代疫苗有望改善患者结局与生活质量。
研究设计与样本
- 本文为观点类文章,分析癌症疫苗试验及不同疫苗方法的优势与局限。
主要发现
- 辅助治疗中,针对黑色素瘤和胰腺癌的疫苗似乎正在减少微小残留病和复发。
- 大转移灶环境中,原位疫苗在晚期肺癌、乳腺癌和淋巴瘤中诱导了系统性消退。
- 通过更深入理解肿瘤免疫学关键细胞因子、纳入新型疫苗组分、运用组学和人工智能设计疫苗以及联合免疫检查点阻断,正在开发更有效的癌症疫苗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccines have had a major impact on the control of infectious disease, most recently by helping to combat the COVID-19 pandemic. Prophylactic cancer vaccines have prevented several malignancies by protecting against cancer-causing pathogens. By contrast, therapeutic vaccines training the immune system to eliminate established tumours are now showing real promise in clinical settings. In the adjuvant setting, vaccines against melanoma and pancreatic cancer appear to be reducing minimal residual disease and relapse. In the macrometastatic setting, in-situ vaccines have induced systemic regressions in advanced-stage lung and breast cancers and lymphomas. More effective cancer vaccines are being developed through having a deeper understanding of crucial cellular factors in tumour immunology, the incorporation of newer vaccine components to effectively mobilise and activate cells, the use of omics and artificial intelligence in vaccine design, and addition of immune checkpoint blockade. In this Viewpoint, we analyse cancer vaccine trials, the strengths and limitations of different vaccine approaches, and we discuss how the next generation of cancer vaccines can help improve patient outcomes and quality of life.
引用
- Pail O, Lin MJ, Anagnostou T, et al. Cancer vaccines and the future of immunotherapy. Lancet. 2025. PMID: 40541217. doi:10.1016/S0140-6736(25)00553-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。